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Abstract
Glioblastoma is the most frequent and malignant brain tumor with a wide variety of
morphological  appearances.  For  a  long  time,  the  tumors  were  classified  either  as
primary  (“de  novo”)  glioblastomas  that  develop  rapidly  in  elderly  patients  or  as
secondary  glioblastomas  with  clinical  or  histological  progression  from  low-grade
diffuse astrocytoma or anaplastic astrocytoma. Recent data from the comprehensive
genetic characterization of these tumors identified a number of common and diverg‐
ing  alterations  and pathways  that  allow future  stratification  of  glioblastomas  into
several age-dependent biological subgroups. While the histological classification of
diffuse  gliomas  based  on  the  WHO grading  scheme is  still  necessary,  the  use  of
additional meaningful immunohistochemical (and mutation-specific) markers, such as
IDH R132H, ATRX, and H3F3A K27M, has improved routine diagnosis. In recent years,
the spectrum of clinically relevant molecular markers has expanded. The utility of
MGMT, ATRX, TERT, H3F3A and LOH 1p/19q in predicting prognosis and response
to therapy in routine diagnostic settings is discussed.
Keywords: neuropathology, histopathology, immunohistochemistry, molecular classi‐
fication, glioma
1. Introduction
Gliomas are diffusely growing neoplasms of the central nervous system that present high rates
of  morbidity and mortality.  They are the most  frequent CNS neoplasms,  accounting for
approximately 29% of all CNS neuroepithelial tumors [1]. In contrast to almost all other brain
tumors, such diffuse gliomas are characterized by extensive, diffuse infiltration of tumor cells
into the brain parenchyma—the neuropil. This infiltration is so extensive that even past attempts
with radical resection of a hemisphere were not successful, as the tumors reemerged on the
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contralateral hemisphere [2]. Because of their similarity with non-neoplastic glial cells, these
tumors are considered to be of astrocytic and/or oligodendroglial lineage and do not include
the biologically different group of ependymomas [3]. The most common primary and malig‐
nant brain tumor among this group is glioblastoma, widely known by its acronym “GBM.” The
tumor was  originally  designated as  “glioblastoma multiforme” because  of  the  extensive
variability of tumor histologies. However, some specific (and rare) entities have been isolated
from this umbrella term, and individual glioblastomas can also appear quite monomorphic in
histology. For this reason, the term “multiforme” is no longer in use following the WHO 2007
classification [4].
Glioblastomas are preferentially located in the subcortical or deep white matter of the cerebral
hemispheres, but they may be observed in any other region of the brain, including the
cerebellum and spinal cord [3]. Upon initial presentation, less than 2% of the tumors show
multiple, clearly distant lesions [5]. In our institution, we prefer to use the term “multifocal”
for such lesions without apparent MRI and histological continuum and the term “multicentric”
for tumors with radiologically or macroscopically visible distinct tumor centers that have
developed from a single lesion. Conventional radiological modalities tend to underestimate
the extent of diffuse infiltrative glioma growth. Tumor cells are usually present even outside
the peritumoral areas of low density in CT and hyperintensive regions on T2-weighted images
in MRI [6]. Not surprisingly, the radiological distinction between multifocal and multicentric
gliomas is slightly uncertain. The most extreme example of diffuse infiltrative glioma growth
is represented by gliomatosis cerebri. This diagnosis requires the involvement of at least three
cerebral lobes, usually bilaterally [3]. Because gliomatosis lacks molecular differences between
more circumscribed tumors, this entity will most likely be removed in the next WHO revision.
Unlike secondary/metastatic brain tumors, gliomas usually respect the blood-brain barrier,
and extraneural metastasis, which is extremely rare, occurs due to ventriculo-peritoneal shunts
[6]. In contrast, cerebrospinal fluid spread of glioblastoma cells is occasionally observed, but
it is still far less common than in ependymomas or childhood primitive neuroectodermal
tumors. Common routes of spread of glioblastoma include the fornix, corpus callosum,
anterior commissure, and radiatio optica because of the high affinity of tumor cells to myeli‐
nated structures [7]. Symmetric tumors spread across the corpus callosum are called “butterfly
gliomas.” Tumors that reach the dura often show marked desmoplasia, leading to a firm
texture that resembles gliosarcoma or meningioma [8].
2. Clinicopathological parameters of glioblastoma
Glioblastomas represent approximately 65% of all astrocytic or oligodendroglial neoplasms
[1]. Incidence rates, estimated to be up to 4.6 per 100,000 people, tend to vary by region, with
generally higher numbers in developed countries, increasing with patients' age and showing
a slight predominance for males [9]. The vast majority of tumors are observed in adults, with
a mean age at diagnosis of 61 years. However, GBM can be found in children, and due to their
lower incidence, these tumors are often grouped together with anaplastic astrocytomas and
intrinsic pontine gliomas as high-grade (i.e., WHO grade III and IV) tumors. As a matter of
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fact, comparing clinical and molecular data from such cohorts with adult tumors is difficult.
Generally, a younger age of onset in non-pediatric GBM is one of the strongest predictive
factors of prolonged survival [10]. Despite this fact, surprisingly, many publications do not
include patients' age in multivariate analysis when analyzing biomarkers of patient survival.
While almost all GBM occur sporadically, in individuals with Lynch syndrome, a constitu‐
tional mismatch repair defect results in an increase of brain tumors, including GBM, among
families [11]. Glioblastomas have been reported in other inherited tumor syndromes, including
neurofibromatosis type 1, Li-Fraumeni and Turcot-Syndrome and multiple enchondromatosis
[3].
Because diffuse astrocytomas show a tendency to progress to a more malignant phenotype
during disease progression, these tumors end up as the so-called secondary glioblastomas,
(10–15% of all glioblastomas). However, the vast majority of glioblastomas (85–90%) develop
without a precursor lesion—the so-called “de novo” or primary glioblastoma [12]. Based
purely on histology, primary and secondary glioblastomas cannot be distinguished and it is
expected will be rather separated in future WHO classification that glioblastomas will be
separated by their molecular profile, than their clinical history (this will be discussed in more
detail below). While there is no doubt that oligodendrogliomas undergo a similar malignant
tumor progression as astrocytic neoplasms, there is still debate about how many of these truly
develop into glioblastomas. As there is some overlap in preoperative imaging of GBM with
solitary metastases or lymphomas, intraoperative cytology and frozen sectioning may help in
the rapid diagnosis and decision making in neurosurgical procedures. In many cases, nuclear
atypia, uneven cell distribution, and the presence of fibrillary processes should guide diag‐
nosis. However, cellularity in frozen sections is often underestimated as a result of artifactual
spaces (Figure 1).
Figure 1. Glioblastomas have a poor prognosis. Kaplan–Meier overall survival Tübingen glioblastoma cohort (n = 205,
median survival: 417 days, all cases IDH-wild-type, age <45 years, primary cases).
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In newly diagnosed glioblastoma, current therapeutic strategies include surgery (from biopsy
to gross total resection, depending on location, which itself is a prognostic marker [13])
followed by concomitant radiotherapy with temozolomide (TMZ) and up to 6 cycles of TMZ
maintenance therapy in patients ≤65 years with a median overall survival (OS) of 14.6 months
[14].
In addition to the well-established prognostic factors of survival in GBM patients, such as
age, extent of resection (EOR), Karnofsky performance scale (KPS), and the treatment mo‐
dality, molecular alterations (i.e., IDH mutation and MGMT gene promoter methylation,
which we will discuss in more detail below) represent not only new significant prognostic
factors of survival but also predictors of therapeutic responses in subgroups of GBM.
MGMT gene promoter methylation status is a strong prognostic marker of survival in GBM
with a median OS of 12.6 months in unmethylated and 23.4 months in methylated GBM
treated by concomitant radio-chemotherapy with TMZ. Moreover, MGMT gene promoter
methylation status also serves as a predictor of the response to TMZ therapy. In patients >65
years of age exclusive radiotherapy or chemotherapy is indicated according to the MGMT
gene promoter methylation status. Patients with methylated GBM most benefit from mono-
therapy with TMZ, and patients with unmethylated GBM demonstrated the highest survival
profit by exclusive radiotherapy [15, 16]. Recurring tumors with a methylated MGMT pro‐
moter (i.e., the silencing of the antagonistic effect of this repairing enzyme on alkylating che‐
motherapy) may thus benefit from a second round of treatment with TMZ [17].
Approximately 30–35% of glioblastoma samples contain a methylated MGMT promoter
[18]. However, tumor treatment in diffuse gliomas lacks a persistent therapy response [19],
which is why there is an increase of studies with direct (“personalized”) targeting of driver
mutations in glioblastomas. Alternative treatment approaches include the application of on‐
colytic parvoviruses to induce tumor cell cycle arrest and cell death [20], the application of
low-energy alternating electric fields that affect dividing cells' viability [21], and the applica‐
tion of local hyperthermia induced by superparamagnetic iron oxide nanoparticles coated
with hydrophilic polymers subjected to an alternating magnetic field [22].
One of the primary mechanisms related to treatment failure and tumor recurrence in GBM,
even in targeted therapies, might be attributed to intratumoral molecular heterogeneity [23]
and the presence of a subpopulation of cancer stem cells that contribute to tumor propagation
and tumor maintenance through their ability to self-renew and differentiate [24].
2.1. Histologic tumor classification
Although serious advances in the neuroimaging of glioblastomas have been made in the past,
histopathologic evaluation of neurosurgically removed tumor specimens is still required for
definite classification and subsequent molecular stratification. In 1979, the World Health
Organization (WHO) issued a publication for the classification of tumors of the central nervous
system. This included a grading scheme based on the malignancy of tumor behavior. The
grading of CNS tumors is performed with a four-tiered score, which ranges from grade II to
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grade IV in astrocytic/oligodendroglial tumors, to separate the histologic continuum of diffuse
gliomas according to their expected clinical behavior. Grade IV has the worst prognosis and
is reserved for glioblastoma [3].
On macroscopic view, the necrotic center of the tumor is often surrounded by a macroscopi‐
cally visible gray rim and surrounded by yellowish-grayish texture blending into the sur‐
rounding white matter. Black hemorrhagic streaks and thrombosed veins are typically
observed in glioblastomas [4]. Glioblastomas' tumor borders are usually diffuse, but rare cases
(especially giant cell glioblastomas and gliosarcomas) can be very circumscribed, mimicking
a carcinoma metastasis.
The astrocytic heritage of the glioblastoma is best appreciated in cases with prominent
eosinophilic cytoplasm of pleomorphic tumor cells resting on a fibrillary background, but this
is not the rule for all tumors [25]. As expected in a malignant tumor, marked nuclear atypia
and elevated mitotic activity is common. The presence of microvascular proliferations, necrosis
or both are required to determine the diagnosis of GBM [3, 4]. Intraoperative consultation with
cryosection and smears can provide an initial histological diagnosis and the grade of malig‐
nancy. Therefore, intraoperative consultation is useful for neurosurgeons to a) confirm the
region of interest in stereotaxic surgery, to b) decide the EOR in relation to the risk of devel‐
oping new neurological deficits in patients with tumors in eloquent regions, and to c) distin‐
guish between tumor infiltration and reactive astrocytosis.
In absence of these hallmarks, tumors must be classified as anaplastic astrocytomas, even when
subsequent molecular data indicates that such tumors are underclassified glioblastomas [26].
On average, three pseudopalisading necroses are present in a glioblastoma specimen. Pseu‐
dopalisading cells are usually less proliferative and exhibit higher rates of apoptosis due to
hypoxic conditions. More than half of the palisades show a central vascular lumen, and in
approximately 20%, intravascular thrombosis is also observed [27]. The presence and extent
of necrosis is an adverse prognostic factor [3]. Vascular proliferation in the form of glomeruloid
bodies in glioblastomas is observed more frequently than in tumors from any other organ
system [28]. Vascular proliferations tend to accumulate in the peripheral region of high
cellularity corresponding to the contrast-enhancing ring observed in radiological images [3].
In addition to intrinsic tumor growth, the so-called secondary properties (“Scherer signs”)
indicate the presence of glioblastoma: perineuronal satellitosis, subpial growth along cortical
surfaces and perivascular and intrafascicular growth along myelinated fibers in white matter
tracts, mostly characterized by small undifferentiated cells [29]. In the spinal cord, tumor cells
might extend into the subarachnoid space [4].
Tumor appearance can be so heterogeneous that diagnosis is often based on tissue patterns
rather than individual tumor cell morphology. The 2007 WHO classification recognizes two
distinct morphological variants, the giant cell glioblastoma and the gliosarcoma. The giant cell
glioblastoma is often subcortically located, and the aptly named cells are regarded as a type
of regressive change and harbor a high frequency of Tp53 mutations [3]. Diagnosis requires
the presence of giant, often multinucleated cells in more than 50% of tumor cells that can be
associated with reticulin deposits [30]. These tumors need to be distinguished from the more
benign subependymal giant cell astrocytoma or pleomorphic xanthoastrocytoma. Gliosarcoma
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consists of often densely interwoven malignant glial and mesenchymal components and
account for up to 2% of all glioblastoma samples. The alternating reticulin-free glial and
reticulin-containing mesenchymal deposits can be additionally visualized through GFAP
immunohistochemistry [3]. While the OS in giant cell glioblastoma is somewhat better, data
from a large retrospective study (and others) did not show significant differences for gliosar‐
comas [31]. Currently considered as a pattern, not a morphological variant, gliomas can show
focal areas of epithelial differentiation that range from the positive immunoreactivity of
epithelial antigens to adenoid or squamous formations, leading to the misdiagnosis of
carcinoma [32]. Among this group, the epithelioid GBM stands out with a younger age of onset
and a high percentage of therapeutically relevant BRAF V600E hotspot mutations, and it is
very likely that this tumor will become a third glioblastoma variant in the upcoming 2016 WHO
classification [32]. These closely packed tumors have variably lipidized, small- to medium-
sized cells with rounded cytoplasmic profiles, eosinophilic cytoplasm without stellate
processes, and the absence of interspersed neuropils [33].
Small cells with little cytoplasm can appear so monomorphous that small cell glioblastomas
mimic anaplastic oligodendrogliomas. Such tumor cells intermingled with gemistocytes are
more likely observed in glioblastomas developing from a previous lower-grade gemistocytic
astrocytoma. However, the tumors show the same aggressive course as primary GBM [34]. In
some tumors, the nucleus-to-cytoplasm ratio is so high that sharply demarcated hypercellular
tumor nodules with evidence of neuronal differentiation are present. These clonally expanded,
often myc-amplified, so-called PNET components have a high risk of cerebrospinal fluid
dissemination [35]. Some tumors may show prominent perivascular rosettes resembling
anaplastic ependymomas but usually lack the more uniform roundness of ependymal tumor
cells. Tumor cells can be elongated and arranged in fascicles so that upon first viewing them,
a sarcoma comes to mind. In up to 15% of the tumors, perinuclear halos around nuclei in
glioblastomas may resemble oligodendrogliomas on first viewing; however, the tumor nuclei
usually lack the monotonous roundness of true oligodendrogliomas. Such tumors are often
called glioblastoma with oligodendroglial component because initial studies suggested that
these tumors might have a better prognosis than standard glioblastoma. Comprehensive
reviews, including molecular analysis, indicated a pathogenetically heterogeneous group
(including misdiagnosed oligodendrogliomas) without a prognostic role [36]. Another
occasionally encountered pattern is the presence of adipocyte-like tumor cells that are clearly
of astrocytic origin. These tumors are not genetically distinct from conventional glioblastoma
[37]. In some cases, the xanthomatous/lipomatous changes are so prominent that the glial
nature of these tumors is obscured [38]. Other morphologic variants include granular cell
astrocytoma, which is characterized by large, PAS-positive cells with a degenerative granular
lysosomal content. These look similar to the benign granular cell tumor of the pituitary stalk
[39]. Metaplastic transformation can be so strong that chondroid and osseous formations in
gliomas are possible [40]. Rare cases may show melanotic differentiation [41] or a rhabdoid
phenotype with focal loss of INI-1 as observed in atypical teratoid/rhabdoid tumors (Fig‐
ure 2) [42].
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Figure 2. Glioblastoma histology consists of an anaplastic glial tumor with increased cellularity and mitotic activity
(A), areas of pseudopalisading necrosis (B). The tumor diffusely invades the brain and has proliferating vessels (C).
Morphological variants include giant cell glioblastoma (D), small cell glioblastoma (E), glioblastoma with PNET com‐
ponent (F), with oligodendroglial component (G), with adenoid features on a myxoid background (H), granular cell
glioblastoma (I), and epithelioid glioblastoma (K).
2.2. Immunohistochemistry
In many instances, the diagnosis of GBM is straightforward in histology. However, confirma‐
tion of the diagnosis with a routine immunohistochemistry panel is mandatory for laboratory
quality and improves diagnostic accuracy. Furthermore, some stains have not only diagnostic
but also a prognostic role, and their results should be communicated back to clinicians.
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The immunoprofile of the glial markers GFAP and EAAT1 in GBM is similar to astrocytomas
[43]. In the vast majority of glioblastomas, these antigens are strongly expressed in the
cytoplasm of the tumor cells, but they may be occasionally lacking (especially in small cell
glioblastomas). The alternatives S-100, WT1, and MAP2 are less specific. Strong MAP2 and
WT1 immunoreactivity in cytoplasmatic cell processes is observed in 90% of glioblastomas
and is helpful in discriminating GBM from oligodendrogliomas [44, 45]. Vimentin is very
unspecific and has no diagnostic value in brain tumors. Cytokeratin expression in glioblasto‐
mas (especially in giant cell glioblastomas and glioblastomas with epithelial differentiation) is
an important diagnostic pitfall and should not lead to the erroneous diagnosis of carcinoma
metastasis [32]. Dot-like EMA immunoreactivity is less frequently observed in GBM than in
ependymomas, where usually more than 5 EMA-positive dots per high-power field are
observed [46].
Identifying axons with neurofilament stains within the tumor can support the diffuse growth
of GBM. In gliosarcomas, GFAP is lacking in reticulin-rich, sarcomatous areas. Usually 15–25%
of the nuclei are MIB-1 positive, but the tumor proliferation rate varies greatly between
individual GBM. We have observed gemistocytic tumors with less than 5% positive cells and
small cell glioblastomas with 90% proliferating cells [25]. Recurrent tumors with history of
previous radiation may show little proliferating activity. Because of inconsistent laboratory
techniques and varying evaluation methods, MIB-1 immunoreactivity has little prognostic
relevance. Nuclear Tp53 immunoreactivity in primary GBM is less present than in astrocyto‐
mas and their GBM recurrences, but it may be considerably high in giant cell glioblastomas.
Tp53 expression alone is not an independent prognostic marker, but in combination with a
methylated MGMT promoter, p53 nuclear staining in more than 50% of tumor cells indicates
a less favorable course, similar to GBM with an unmethylated MGMT promoter [47]. It is
noteworthy, that not all p53 immunoreactive tumors contain mutations in the Tp53 gene [48]
and molecular determination of p53 mutation status in GBM does not correlate with patients'
outcome [49]. Several studies have attempted to obtain the MGMT status by immunohisto‐
chemistry for MGMT protein expression, but results are hampered by diverging cut-off values
and poor correlations with clinical outcome. MGMT immunohistochemistry therefore should
be avoided unless there is a consensus with clinical data [50]. Microglial markers, such as CD68-
and CD163-positive cells, are regularly found in GBM and can be very widespread, especially
in tumors with granular cell components, and must be distinguished from demyelinating
lesions.
The NADP-dependent enzymes IDH1 and IDH2 catalyze the conversion from isocitrate to
alpha-ketoglutarate. Mutations of the catalytic center in brain tumors result in the accumula‐
tion of the oncogenic metabolite D-2-hydroxyglutarate [51]. Because IDH1 mutations are
associated with a significantly more favorable outcome in GBM, confirmed in several inde‐
pendent studies, IDH analysis has become the major biomarker in neuropathology practice
[52, 53]. The prognostic role of IDH1/2 mutations becomes obvious in WHO grade IV IDH-
positive glioblastomas because they show a better prognosis than WHO grade III IDH-negative
anaplastic astrocytomas [54]. The upcoming 2016 WHO tumor classification therefore sepa‐
rates glioblastomas according their IDH status. The vast majority of IDH1 hotspot mutations
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lead to a distinct amino acid substitution on codon 132 (Arg132His), for which a mutation-
specific antibody is available [55]. This antibody, however, does not recognize other non-
canonical IDH1 and IDH2 mutations, and negative staining results do not imply an IDH wild-
type status. IDH1 R132H antibody expression is found in 4% of primary and in 71% of
glioblastomas with a lower-grade precursor [55]. In elderly GBM patients above 65 years, the
incidence of IDH mutations is rare—one study reported only 2 positive cases out of 167
samples, accounting for the unfavorable prognosis of this age class [56]. Another important
clinical aspect is the association of epileptic seizures in IDH1 mutant tumors (Figure 3) [57].
Figure 3. Immunohistochemistry: (A) Limited GFAP expression in a glioblastoma with an oligodendroglial compo‐
nent. The absence of an IDH mutation and partial 19q deletion excluded pure oligodendroglioma in this case. (B) Ele‐
vated proliferative activity (MIB-1 index) in the same case. (C) Prognostically relevant IDH1 R132H expression in a
glioblastoma arising from a grade II astrocytoma seven years ago. The same case shows nuclear ATRX loss in tumor
cells (D).
Some studies aimed to identify antigens to detect the tumor subpopulation with stem cell-like
properties, i.e., the cells that have a marked capacity for proliferation, self-renewal, and
differentiation. In glioblastoma, the most widely propagated marker for cancer stem cell ability
is CD133 along with SOX2 and nestin [58]. However, recent studies indicate that CD133-
negative tumor cells may also have stem cell abilities and that different subtypes associated
with divergent molecular glioblastoma profiles, discussed below, may exist [59].
2.3. The genetic landscape
Like other tumors, GBM shows an accumulation of several epigenetic and genetic alterations
in neoplastic cells within the brain. Recent data from the comprehensive multiplatform
genomic characterization of GBM samples identified a number of common and diverging
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alterations and indicate that glioblastoma consists of biologically heterogeneous subgroups
with similar histological appearances. The pilot project of The Cancer Genome Atlas
Consortium in 2008 analyzed more than 20000 genes in 90 primary glioblastomas and
identified the most common somatic genetic alterations/mutations: Tp53 (42% of the tumors
mutated), PTEN (33%), NF1 (21%), EGFR (18%), RB1 (11%), and PI3K-pathway genes (7–10%)
[60]. Interestingly, Tp53 mutations are found in almost all GBM with a giant cell component
[61]. In addition, pediatric glioblastomas also show a high frequency of Tp53 mutations, as in
up to 60% of tumors examined [62].
The most surprising finding was the discovery of isocitrate dehydrogenase (IDH) mutations
that occurred in younger patients; these mutations are always heterozygous and are associated
with an increase in OS [63, 64]. So far, several hotspot mutations were identified in the catalytic
active centers in IDH1 R132, IDH2 R140, and R172 codons, and the most common, R132H,
comprises over 80% of all mutations observed to date. The IDH1/2 mutations are present in
50–88% of the so-called secondary glioblastomas (the same point mutation is always present
in lower grade precursor tumors, and in cases of a IDH1 R132C mutation, strongly associated
with an astrocytoma phenotype). In contrast, IDH1 mutations are observed in only 3–7% of
primary glioblastomas and gliosarcomas [54, 65]. In these tumors, IDH2 mutations are
virtually absent, except for a single reported case. There is ongoing discussion of whether
anaplastic astrocytomas that are IDH1/2 wild-type should be considered glioblastomas
without vascular proliferation and/or necrosis because they show the same clinical course and
also contain similar genomic alterations as primary GBM. Because IDH1 R132H also represents
a tumor-specific antigen, immunotherapy trials currently aim at vaccination to induce
antitumor immunoreactions [66].
The activation of receptor tyrosine kinases (RTKs) and the associated RAS/PI3K signaling
pathway are common events in GBM. Approximately 45–50% of all primary GBM show high-
level genomic amplification of epidermal growth factor receptor (EGFR). Among 30–50% of
these amplified cases, intragenic rearrangements with the deletion of exons 2–7, the EGFRvIII
variant is detected as a late event. The resulting overexpression leads to the constitutive activity
of the receptor in the absence of its ligand and trigger the downstream pathways, resulting in
increased cellular proliferation and radiation resistance of the tumor [67]. GBM with small cell
morphology are often EGFRvIII-positive tumors [34]. Another important fact is that EGFR
mutations in GBM significantly differ from those mutations found in other cancer types, such
as non-small-cell lung cancer, where mutations are often located in the intracellular domain
[26].
Like EGFR, other RTKs, such as PDGFR and MET, are often amplified in GBM. Platelet-derived
growth factor receptor α amplification is significantly enriched for pontine tumors and the
pediatric GBM cohort. These tumors are often grouped by the German Cancer Research Center
(DKFZ) tumor methylation profiles as RTK class I tumors, while EGFR amplified tumors are
classified as RTK-II tumors [68]. Approximately 40% of all PDGFR amplified tumors contain
an intragenic deletion of exons 8 and 9 in PDGFRA, which induces an aggressive growth
phenotype. Detailed cellular analysis in GBM samples showed that independent focal
amplification of PDGFR α and EGFR could coexist in the same tumor [69].
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Other common oncogenic alterations in GBM involve the extended PI3K-AKT-mTor and RAS-
MAPK pathways. Mutations of the important primary negative regulator PTEN are found in
up to 30% of GBM, and the RAS antagonist neurofibromin 1 (NF1) is mutated in 15% of all
primary tumors. NF1 germline mutations result in neurofibromatosis type 1, and although
rare in comparison to the prevalence of pilocytic astrocytoma, the occurrence of GBM in NF1
syndrome has been reported in a handful of cases [70]. The loss of NF1 is usually associated
with concomitant Tp53 mutations, and the additional deletion of PTEN results in the progres‐
sion of astrocytoma to GBM [48]. Interestingly, PTEN loss and subsequent PI3K-AKT pathway
activation results in increased expression of the programmed death ligand-1 (PD-L1), which
in turn contributes to GBM immunoresistance and immune escape [71]. Consequently, studies
with immune-checkpoint inhibitor treatment in GBM are currently ongoing, although there
are conflicting data on the prognostic role and predictive role of PD-L1 gene and protein
expression in glioblastoma [72].
Up to 78% of GBMs show alterations of the retinoblastoma (Rb)/CDKN2A-p16ink4a pathway
[73]. This pathway plays a central role in proliferation and cell cycle regulation, and alterations
include deletions and point mutations in several involved genes. Interestingly, the Rb pro‐
moter is far less methylated in primary GBM than in secondary GBM, consistent with the
observation that the CDKN2A-p16ink4a gene is affected by the commonly observed chromoso‐
mal 9q loss in primary GBM [74]. Although CDKN2A deletion is associated with tumor
progression of astrocytomas to GBM and is one of the key molecular marker used to determine
a “classical GBM,” its prognostic role remains to be elucidated.
Mutations in the promoter region of the telomerase reverse transcriptase (TERT), the catalytic
subunit of the telomerase complex, are found in 70–80% of GBM. Similar high frequencies in
brain tumors are only observed in oligodendrogliomas [75]. The presence of a TERT mutation
in IDH1/2 wild-type tumors is associated with poor outcome and indicates underdiagnosed
glioblastoma in a small specimen with otherwise low-grade glioma [76]. TERT itself may also
contribute to glioma genesis, as there is evidence that the TERT SNP genetic rs2736100 may
influence glioma risk, although it is not a prognostic marker itself [77]. Glioblastomas that do
not carry a TERT mutation were recently designated as “triple negative” tumors, i.e., lacking,
IDH mutation, 1p/19q codeletion and TERT mutation, again highlighting the importance of
these three markers for tumor stratification. TERT mutations are rare in pediatric glioblasto‐
mas, where whole exome sequencing recently identified H3F3A mutations, often combined
with Tp53 and ATRX/DAXX alterations [78]. The H3F3A mutations are concentrated on two
hotspots, K27M and G34V/R, which are mutually exclusive. Both show distinct clinicopatho‐
logical tumor profiles. H3F3A K27M mutations alter the di- and tri-methylation state of
endogenous histone H3 at the Lys27 position and are mainly found in pontine and thalamic
tumors [79]. In contrast, the mainly supratentorially located H3F4A G34 mutant tumors
presented as a histopathologically heterogeneous group of neoplasms, overlapping classical
GBM with central nervous system primitive neuroectodermal tumors (CNS-PNET) [80]. There
is growing evidence that G34 mutations may have an alternative mechanism to drive MCYN
overexpression for tumor growth [68]. While K27M mutant tumors show a very unfavorable
course, the three-year survival rate without this mutation in the pediatric cohort is approxi‐
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mately 70% [81]. Alpha-thalassemia C-linked mental retardation (ATRX) mutations are found
in approximately 30% of pediatric GBM and in 6% of adult glioblastoma. Interestingly, in
pediatric GBM, ATRX mutations occur around a hotspot near the carboxy-terminal helicase,
while they are widely distributed across the gene in adult GBM [82].
ATRX and its binding partner DAXX (death-associated protein) belong to a complex with a
role in regulating chromatin remodeling, nucleosome assembly and telomere maintenance.
ATRX mutant tumors are associated with alternative lengthening of telomeres, the so-called
ALT phenotype [78]. Because nuclear ATRX is diminished in tumors with the ALT phenotype,
ATRX immunohistochemistry has become useful in identifying potential IDH mutants, H3F3A
alterations or secondary GBM (usually showing ATRX loss and being mutually exclusive of
LOH 1p/19q) [83]. Furthermore, retrospective analysis of ATRX in samples from the NOA-04
clinical trial showed a survival benefit of ATRX mutant tumors [84].
2.4. Epigenetics and molecular profiling
The DNA repair enzyme O-methylguanine-DNA methyltransferase (MGMT) removes alkyl
groups from the O6 position. Methylation of the MGMT promoter region results in decreased
MGMT activity, which in turn results in decreased tumor resistance to alkylating agent therapy
with TMZ, and is therefore a predictive molecular marker [36]. Usually, MGMT is determined
in formalin-fixated paraffin-embedded specimens, and approximately 40% of all primary GBM
carry a methylated promoter [18]. Less than 15% of gliosarcomas have a methylated phenotype
[65]. In pediatric glioblastomas, approximately half of the tumors are methylated, mainly due
to the association between H3F3A mutations and the methylated MGMT profile, but the
prognostic and predictive role of MGMT methylation in children remains a matter of contro‐
versy [62, 68]. MGMT analysis is essential for almost all clinical studies and one of the most
requested molecular analyses in routine neuropathology practice.
Unsupervised hierarchical clustering of GBM identified four tumor subclasses called proneu‐
ral (characterized by mostly IDH/Tp53 mutations, PDGFRα amplifications, PI3K pathway
dysregulation), classic (large-scale EGFR amplification, PTEN, and CDKN2A loss), mesen‐
chymal (NF1, Tp53, and CDKN2A alterations), and neuronal (currently no specific genetic
alterations). As expected from the IDH mutation data, the patients with a proneural tumor
profile were younger and showed the best outcome [60]. The proneural group exhibited a
robust hypermethylated glioma-CpG island methylator phenotype (G-CIMP) that is also
present in most secondary GBM indicating a common gliomagenesis for IDH-mutated GBMs
[85]. Glioma stratification according the IDH status therefore has widely replaced the previous
clinic-based separation of primary and secondary GBM. Computational modeling to predict
the temporal sequence of driver events during tumorigenesis indicates that most non-GCIMP
mesenchymal GBMs arise from a PDGFA-driven proneural-like precursor though additional
NF1 loss [86]. However, assignment with established glioblastoma subtype classifiers becomes
difficult in cases with substantial tumor heterogeneity and may change further during patient
treatment [73].
Glioblastoma intratumoral heterogeneity contributes to therapy resistance. This is exemplified
in a whole genome sequencing report that showed not only extensive mutational and copy-
Neurooncology - Newer Developments14
number heterogeneity within the primary tumor but also uncovered the recurrence of a
double-minute chromosome converging on the KIT/PDGFRA/PI3K/mTOR axis, superseding
the IDH1 mutation in dominance in a mutually exclusive manner [87]. Despite targeted
therapy with imatinib, the patient succumbed to progressive disease. Another good example
is the recent discovery that EGFRvIII mutant cells are expressed only in a fraction of GBM cells
of EGFR amplified tumors and enhance the proliferative activity of their neighboring EGFR
wild-type tumor cells though cytokine secretion [88]. Because the majority of GBMs exhibit
the activation of three or more RTKs, this highlights the need for the combined approach of
several specific inhibitors for successful treatment.
Although there is increasing knowledge of divergent molecular alterations in histologically
similarly appearing glioblastoma specimens, clinical decision-making on molecular alterations
of glioblastoma subtypes is still limited. Notable exceptions include the determination of
chromosomal allelic losses in 1p/19q in younger GBM patients, as such tumors respond far
better to a combined Procarbazine-CCNU-Vincristine (PCV) therapy regimen [89]. The 1p/19q
co-deletion is strongly associated with oligodendroglial tumor morphology and will become
a diagnostic marker to be reassigned in future glioblastoma with this signature into the
anaplastic oligodendroglioma group [26]. Up to 75% of co-deleted tumors also show either
additional IDH1 or IDH2 mutations [90]. This combined molecular signature is so robust and
remains visible in tumor recurrences, even in cases with increased intratumoral heterogeneity,
and overlaps with “proneural” expression profile of the TCGA genomic landscape [91].
2.5. Conclusion
Glioblastomas have an extensive variety of histological appearances and divergent immuno‐
histochemical and molecular profiles, making diagnosis somewhat difficult for those who are
not familiar in working with brain tumors. The histological classification of diffuse gliomas
based on the latest WHO grading scheme is a prerequisite to optimal decision-making
regarding patient treatment. In addition to core features (microvascular proliferations,
necrosis, and secondary structures of Scherer), the clinically relevant pattern and variants
(gliosarcoma, giant cell glioblastoma, epithelioid, small cell GBM, and GBM with PNET
component) should be clearly depicted in neuropathology reports. Immunohistochemistry
and molecular biology have contributed to an improved classification and were shown in some
cases to be of prognostic value. A panel of different antibodies is very helpful in securing the
diagnosis and avoids potential differential diagnostic pitfalls. The advantages and limitations
of the most commonly used antibodies, such as GFAP, WT1, MAP2, MIB-1, P53, IDH1R132H,
and ATRX, in GBM have been outlined. The GBM subtype, patient's age, tumor location, and
staining results subsequently guide a staged approach to therapeutically relevant molecular
analysis, such as the 1p19q codeletion, MGMT promoter methylation, H3F3A screening, TERT
promoter and IDH hotspot mutations. The classic concept of primary and secondary glioblas‐
tomas has been challenged by the discovery of clinically divergent molecular GBM cohorts,
providing a good example of “convergent evolution showing a similar phenotype of geno‐
typically different tumor cells” [92]. The implementation of these additional molecular
markers into routine diagnoses has already started, including the routine determination of
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MGMT gene promoter methylation status to guide therapy and the re-classification of tumors
for appropriate treatment according to LOH1p/19q analysis, and it is expected to further
evolve. The heterogenous landscape within and across GBMs underscores the difficulty in
developing multimodal targeted therapies and is also a challenge to stratify patients for clinical
trials. However, the recent identification of recurring driver mutations as illustrated here
provides a rationale to identify tumor-specific peptides and antibody targets that may improve
glioblastoma treatment.
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